Spotlight Series on Hepatitis C


How Will New Hepatitis C Drug Pricing Affect Health Care Costs?

July 16, 2014


A New Era in Hepatitis C Treatment

A New Era in Hepatitis C Treatment

Until recently, treating hepatitis C (HCV) required 24 weeks or more of weekly injections with a regimen including peginterferon alfa. These drug combinations often failed to cure the HCV infection and came with many side effects.

However, it's been a breakthrough year for HCV treatment, with many new, more effective and safer options taking the spotlight. Spearheading the way has been sofosbuvir (Sovaldi), a nucleotide polymerase inhibitor that allows for oral dosing, interferon-free treatment for many and a shorter treatment course.

But the drug's introduction -- and its high baseline price tag -- has stirred considerable debate. Let's examine the brief history of sofosbuvir and how its controversial price could impact future health care costs.

Get Started

This article was provided by

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.